Proponen un cambio de paradigma en el desarrollo de fármacos antiarrítmicos en insuficiencia cardíaca

by CIMA - Centro de Investigación Médica Aplicada

El desarrollo de estos nuevos antiarrítmicos supondría una disrupción en un área en la que, desde hace más de tres décadas, no se han desarrollado fármacos alternativos a los comercializados qu...

Read more

Accure Therapeutics Obtains €1.5 Million in Grants to Accelerate Development of Its Parkinson’s Drug ACT-02

by Parc Científic de Barcelona

The funding will drive two preclinical development programs for its groundbreaking drug, ACT-02—an innovative compound with potential disease-modifying properties. ACT-02 functions as an inhibitor o...

Read more

Funditec Health opens new lab at the Ilumina building, BASID Campus in Barcelona

by Funditec

From this new headquarters, Funditec Health, led by Dr. Domingo Gargallo-Viola, will continue its work in translational research, therapeutic development, and health innovation, heading both national ...

Read more

ORYZON announces first patient dosed in NCI-sponsored Phase I/II clinical trial of iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer

by Oryzon Genomics

Oryzon Genomics announced today that the first patient has been dosed in a Phase I/II trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with immune checkpoint inhibi...

Read more

Three Asabys-Backed Biotechs Featured in Nature, Showcasing Spain's Scientific Innovation

by Asabys Partners

Nature, the world's leading scientific journal, has spotlighted three Barcelona-based biotech startups, Ona Therapeutics, Nuage Therapeutics, and SpliceBio, in a recent article highlighting Spain's bu...

Read more

ORYZON continues to strengthen its patent portfolio for vafidemstat.

by Oryzon Genomics

The patent, titled “Methods of treating Attention Deficit Hyperactivity Disorder using KDM1A inhibitors such as the compound vafidemstat”, covers the use Oryzon’s LSD1 inhibitor, vafidemstat, cu...

Read more

ORYZON Raises €30 Million in Capital Increase

by Oryzon Genomics

It has been announced today the successful completion of a €30 million capital increase through the issuance of 12,765,958 new shares, priced at €2.35 per share. This pricing reflects a 15.44%

Read more

Thermo Fisher Scientific Leverages Integrated Solutions to Accelerate the Development of Biologic Therapeutics

by Thermo Fisher Scientific

Enhanced platform technology and the addition of a robust, high-quality CHO K-1 cell line decreases lead time to Investigational New Drug (IND)

Read more

Oniria Therapeutics raises $2 million for oncology drug

by ONIRIA Therapeutics

Founded in 2022 as a spin-off from Vall d'Hebron Institut d'Oncologia, the University of Barcelona and Icrea, Oniria Therapeutics specialises in the development of targeted therapies to eliminate pers...

Read more

Un nuevo fármaco experimental mejora la función motora y prolonga la vida en un modelo de ELA

by Biodonostia

Un estudio colaborativo publicado recientemente en la revista British Journal of Pharmacology, ha mostrado la capacidad de la molécula MP-010, desarrollada por la spinoff del IIS Biogipuzkoa Miramoon...

Read more

ORYZON awarded 13.26 million € through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)

by Oryzon Genomics

Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Telum Therapeutics Secures €18 Million...

by Telum Therapeutics

Telum Therapeutics, a biotechnology company leveraging proprietary met...

Photos Stream